Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal ... - PubMed
WEBOct 1, 2015 · Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with advanced solid tumors. Experimental design: In a 3 + 3 dose escalation study, 10 patients received pembrolizumab 1, 3, or 10 mg/kg intravenously every 2 …
Pembrolizumab for Early Triple-Negative Breast Cancer
WEBFeb 26, 2020 · Pembrolizumab (Keytruda, Merck Sharp & Dohme), an anti–programmed death 1 (PD-1) monoclonal antibody, has been shown to have antitumor activity and a range of mainly low-grade toxic effects in...
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
WEBMay 21, 2015 · As part of the large, international, phase 1 KEYNOTE-001 trial, we evaluated the side effects, safety, and antitumor activity of pembrolizumab in patients with advanced non–small-cell lung...
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 …
WEBSep 30, 2015 · This report details the first-in-human experience for pembrolizumab in patients with advanced solid tumors, including in-depth pharmacokinetic and pharmacodynamic analyses. No dose-limiting toxicities occurred, and promising antitumor activity, including complete responses, were observed.
Pembrolizumab for Persistent, Recurrent, or Metastatic …
WEBSep 18, 2021 · Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy.
Merck Receives Accelerated Approval of KEYTRUDA® …
WEBSep 4, 2014 · KEYTRUDA. The approval of KEYTRUDA was based on data from a multi-center, open-label, randomized, dose-comparative study cohort of the ongoing KEYNOTE-001 Phase 1b trial in patients with unresectable or metastatic melanoma and progression of disease. Key eligibility criteria included prior treatment with ipilimumab (two or …
Phase 1 Trial of Pembrolizumab Administered Concurrently With ...
WEBPembrolizumab (Keytruda), a selective humanized monoclonal antibody, directly blocks the interaction between programmed cell death 1 (PD-1) and its ligands, PD-L1 and PD-L2. In phase 3 testing, pembrolizumab led to a significant improvement in overall survival in patients with advanced NSCLC, and those with tumors that have a PD-L1 tumor ...
Merck Presents Three-Year Survival Data for KEYTRUDA® …
WEBOct 16, 2020 · Cohort G of the Phase 1/2, multi-cohort, multi-center, open-label trial evaluated KEYTRUDA in combination with chemotherapy (n=60) versus chemotherapy alone (n=63) as first-line treatment in patients with advanced nonsquamous NSCLC.
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
WEBOn October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
Keytruda-Chemo Combo in Lung Cancer Improves Survival …
WEBNov 13, 2020 · First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people with advanced non-squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 status, results from a Phase 1/2 trial show.
- Some results have been removed
Skip to content